Colorectal Cancer Therapeutics Market Outlook:
Colorectal Cancer Therapeutics Market size was valued at USD 13.6 billion in 2025 and is projected to reach USD 21.7 billion by the end of 2035, rising at a CAGR of 4.8% during the forecast period, i.e., 2026-2035. In 2026, the industry size of colorectal cancer therapeutics is evaluated at USD 14.2 billion.
The escalating instances of colorectal cancers and associated mortalities across all nations are primary drivers behind the robust growth of the market. Colon cancer is the 4th leading cancer in the world. As evidence in 2022, the Global Cancer Observatory report states that nearly 1,142,286 colon cancer were registered in 2022, and the death cases were 538,167. Further, as per the WHO 2022 report, the prevalence of colon cancer in the U.S. in the next five years is estimated to be 562,771. This rise demands the therapeutics, surgery, and the drugs related to the diseases.
According to an NLM article released in September 2024 on colorectal cancer, depicts that by 2030 the colorectal cancer may experience a rise of 71.5% in males and 60.0% in females. To address this issue, new developments in colorectal cancer therapeutics based on the immune therapy and targeted therapies are aiming to overcome the challenges with the less side effects and higher effectiveness. Advanced treatment in targeting RAS mutants by using RAS direct inhibitors, targeting the downstream pathways, and targeting RAS via metabolic pathways is demanding the treatment. On the other hand, the latest drugs approved by the FDA, such as Adagrasib, Alymsys (Bevacizumab), Avastin (Bevacizumab), Bevacizumab, Camptosar (Irinotecan Hydrochloride), Capecitabine, and more, are improving the care and treating the cancer effectively.
